Cellectis S.A. (CLLS) vs VAXART, INC. (VXRT)

Cellectis S.A. and VAXART, INC. are both Biotechnology companies. Cellectis S.A. and VAXART, INC. are of similar size ($92.4M and $90.4M). Cellectis S.A. has negative trailing earnings, so its P/E is not meaningful; VAXART, INC. trades at 2.8×. VAXART, INC. grew revenue faster over the last twelve months: 201.1% against 0.61%. VAXART, INC. has the higher net margin (15.9% vs −102.3%) and the higher return on invested capital (134.6% vs 0.00%). Across the 17 metrics below, VAXART, INC. leads on 17 and Cellectis S.A. on 0.

Valuation

Metric CLLS VXRT Biotechnology median
P/E n/m 2.75 8.68
P/S 1.99 0.44 10.29
P/B 3.09 1.29 2.40
Price to free cash flow n/m 3.19 20.52
EV/EBITDA n/m 0.96 0.68
EV/Sales 0.53 0.18 10.15
Earnings yield (51.91%) 36.36% (28.86%)
Free cash flow yield (36.43%) 31.35% (22.44%)

Profitability

Metric CLLS VXRT Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (90.88%) 16.30% 0.00%
Net margin (102.34%) 15.88% 0.00%
Free cash flow margin (68.63%) 13.74% 0.00%
Return on equity (94.54%) 66.97% (56.66%)
Return on assets (21.02%) 23.44% (49.22%)
Return on invested capital 0.00% 134.59% 0.00%

Growth

Metric CLLS VXRT Biotechnology median
Revenue growth (TTM) 0.61% 201.10% 5.64%
EPS growth (last fiscal year) (63.41%) 121.21% 30.08%
Revenue growth, 5-year CAGR (0.70%) 125.76% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLLS VXRT Biotechnology median
Debt to equity 1.79 0.00 0.00
Current ratio 1.37 1.60 4.72
Net debt to EBITDA 9.54 (2.42) 0.96

Dividend

Metric CLLS VXRT Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric CLLS VXRT Biotechnology median
Market cap 90.41m 92.41m 150.40m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack